CZR heads into the summer with a striking divergence: short sellers are unwinding positions at pace, yet the Street's analyst community just staged one of the most coordinated downgrades the stock has seen in years.
The short-covering story is the clearest signal in the data. Short interest dropped 15% in a single week to 10.4% of free float — falling from roughly 24.9 million shares at the end of May to 21.2 million by June 9. That's a meaningful retreat from a one-month high, and it came in a near-continuous run of daily declines stretching back to June 1. Despite the covering, the absolute level remains elevated; 10% of float is not a number that suggests the short thesis has been abandoned. Borrowing costs have risen 36% on the week to 0.71%, though the absolute rate is still modest. What's notable is how loose the lending market remains — availability has ballooned to 1,464%, up nearly 100% on the week and well above its 52-week floor of 308%, pointing to abundant supply for anyone still looking to establish or rebuild a short position.
Options positioning reinforces the sense that sentiment has shifted sharply toward the bullish end. The put/call ratio hit 0.39 — the lowest reading of the past 52 weeks — nearly two standard deviations below its 20-day average of 0.57. That's a clean reversal from the prior several weeks, when the PCR ran consistently above 0.60. Call demand has crowded out the hedgers, at least in the near term. The stock itself has been restrained, up less than 1% on the week and roughly 5% over the past month, closing at $29.45 — so the options enthusiasm looks more like positioning than a reaction to a big price move.
The Street's message is harder to parse as bullish. Five analysts downgraded CZR between May 29 and June 1 — JPMorgan, Deutsche Bank, Truist Securities, Susquehanna, and CBRE all cut from buy-equivalent ratings to hold, with targets clustering tightly at $31. Wells Fargo lifted its target from $26 to $31 on June 2 but stayed at Equal-Weight. The consensus has landed at 4 buys and 10 holds, with a mean target of $31.87 — about 8% above the current price. The downgrades arrived in the wake of news around the proposed acquisition by Fertitta Entertainment, which would expand the portfolio to over 60 casinos but carries an estimated 12-month regulatory approval timeline. Bears see that deal risk, margin pressure versus peers, and an EV/EBITDA multiple of 8.2x as reasons to stay on the sidelines. Bulls point to the EPS momentum factor score of 99 — near the top of the universe — and a 94th-percentile EPS surprise rank as evidence that the underlying business is performing better than the stock price reflects.
The Fertitta deal dominates the institutional conversation, and ownership data adds a wrinkle: Arini Capital Management added roughly 2.8 million shares in the March quarter, building to a nearly 1.9% stake, while Morgan Stanley trimmed 1.7 million shares over the same period. More recently, independent director Michael Pegram sold 55,000 shares on June 2 for just over $1.6 million — a directional signal worth noting even if the significance score is modest. BlackRock remains the largest holder at 12.5% after adding around 213,000 shares as recently as May 31.
Peer PENN gained 6% on the day and sits up 1% on the week, broadly in line with CZR. DKNG was the standout, up 11.3% on the day and 9% on the week — a reminder that the sports-betting adjacent names are catching a different bid. MGM slipped 2.5% on the week, making CZR's flat-to-slightly-up performance look relatively resilient in the regional gaming cohort.
The next scheduled earnings event is July 28. Between now and then, the tension worth watching is whether the analyst downgrades draw fresh short interest back into the 10%-plus zone, or whether the unusual call-side enthusiasm and continued short covering reflect a market that has already priced in the deal uncertainty and is starting to look through it.
See the live data behind this article on ORTEX.
Open CZR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
